AXGN Axogen Inc.

Axogen, Inc. to Participate in the J.P. Morgan 2026 Healthcare Conference

Axogen, Inc. to Participate in the J.P. Morgan 2026 Healthcare Conference

ALACHUA, Fla. and TAMPA, Fla., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that the company will be participating in the upcoming J.P. Morgan 2026 Healthcare Conference.

Axogen’s management is scheduled to present on Thursday, January 15, 2026, at 10:30 AM Pacific Standard Time. Interested parties may access a live audio webcast of the presentation by visiting the “Investors” section of the company’s website at .

About Axogen

Axogen (NASDAQ: AXGN) is focused on the science, development and commercialization of technologies for peripheral nerve repair. With a mission to make nerve repair the expected standard of care, Axogen advances the field through research, education, and collaboration with surgeons and healthcare providers across a global network.

Axogen’s product portfolio includes Avance® (acellular nerve allograft-arwx), Axoguard Nerve Connector®, Axoguard Nerve Protector®, Axoguard HA+ Nerve Protector™, Axoguard Nerve Cap®, and Avive+ Soft Tissue Matrix™. The Axogen portfolio of products is available in the United States, Canada, Germany, the United Kingdom, Spain and several other countries.​

For more information, visit .





Contact:
Axogen, Inc.
EN
17/12/2025

Underlying

AXGNAxogen Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Axogen Inc.

 PRESS RELEASE
Free
AXGN AXOGEN INC.

Axogen Announces Pricing of Upsized $124 Million Public Offering of Co...

Axogen Announces Pricing of Upsized $124 Million Public Offering of Common Stock ALACHUA, Fla. and TAMPA, Fla., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced the pricing of an upsized underwritten public offering of 4,000,000 shares of its common stock at a price to the public of $31.00 per share, before underwriting discounts and commissions. All of the shares to be sold in the proposed offering are to be sold by Axogen. In addition,...

January 22, 2026 1 EN
 PRESS RELEASE
Free
AXGN AXOGEN INC.

Axogen Announces Proposed Public Offering of Common Stock

Axogen Announces Proposed Public Offering of Common Stock ALACHUA, Fla. and TAMPA, Fla., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it intends to offer and sell, subject to market and other conditions, $85.0 million of shares of its common stock in a proposed underwritten public offering. In addition, Axogen intends to grant the underwriters a 30-day option to purchase up to an additional $12.75 million of shares of its common...

January 21, 2026 1 EN
 PRESS RELEASE
Free
AXGN AXOGEN INC.

Axogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter ...

Axogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025 ALACHUA, Fla. and TAMPA, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced preliminary unaudited fourth quarter and full-year 2025 key financials. Preliminary Fourth Quarter and Year-End Key Business Highlights Fourth quarter 2025 revenue is expected to be approximately $59.9 million, which represents a 21.3% increase over the fourth quarter o...

January 12, 2026 1 EN
 PRESS RELEASE
Free
AXGN AXOGEN INC.

Axogen, Inc. to Participate in the J.P. Morgan 2026 Healthcare Confere...

Axogen, Inc. to Participate in the J.P. Morgan 2026 Healthcare Conference ALACHUA, Fla. and TAMPA, Fla., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that the company will be participating in the upcoming J.P. Morgan 2026 Healthcare Conference. Axogen’s management is scheduled to present on Thursday, January 15, 2026, at 10:30 AM Pacific Standard Time. Interested parties may access a live audio webcast of the presentation by visitin...

December 17, 2025 1 EN
 PRESS RELEASE
Free
AXGN AXOGEN INC.

Axogen Announces FDA Approval of Biologics License Application for AVA...

Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx) ALACHUA, Fla. and TAMPA, Fla., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical technologies for the restoration of peripheral nerve function, today announced that the U.S. Food and Drug Administration (the “FDA”) has approved the Biologics License Application (“BLA”) for AVANCE® (acellular nerve allograft-arwx). Avance is an acellular nerve scaffold for the treatment of adult and pediatric patients aged ...

December 4, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch